Bank of America
CLDX icon

Bank of America’s Celldex Therapeutics CLDX Stock Holding History

Bank of America’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-3,247
Closed -$1.73M – 7901
2013
Q3 		$1.73M Buy
+3,247
New +$1.11M ﹤0.01% 3410

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Bank of America's CLDX Position: Q1 2026 in Review

Bank of America increased its Celldex Therapeutics (CLDX) stake by 71% in Q1 2026, buying an estimated $8.01M and bringing the position to 708,647 shares worth $22.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2285.

Bank of America first reported a position in CLDX in Q2 2013 and has held it in 52 quarters since. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Bank of America held 708,647 shares of Celldex Therapeutics worth $22.5M as of Q1 2026.
  • Bank of America bought 293,759 Celldex Therapeutics shares in Q1 2026, an estimated $8.01M.
  • Celldex Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2285 holding.
  • Bank of America first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.